Colorectal Cancer

Given the data presented in this abstract, researchers indicated that it is crucial that further research works toward eliminating these disparities.

Similar health risks for colorectal cancer were observed in both African Americans and whites, though this study indicated that benefit from greater adherence may be higher at the population level for African Americans.

Researchers indicated the importance in improving access to and uptake of CRC screening in these underserved populations.

Although researchers determined which regimen was preferred among physicians in treating metastatic colorectal cancer, they found that shared decision-making should include observation as an acceptable option.

Researchers assessed whether ctDNA could accurately differentiate metastases during the neoadjuvant period after surgery to guide therapy adaptation.

Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.

The use of aspirin 3 or more times a week was associated with a reduction in all-cause, cancer, gastrointestinal cancer, and colorectal cancer mortality in adults 65 and over, according to a study published in JAMA Network Open.

The final results from the evaluation of 42 patients, based on predefined criteria, indicated that the therapy warrants further study.

Screening colonoscopy rates for colorectal cancer increased in low-income Latino populations when accompanied by patient navigation.

Molecular testing provided the clinical data and mutation profile of Chinese patients with colorectal cancer in this retrospective study.

A quality improvement study indicated that nudges in the electronic health record were associated with a significant increase in clinician ordering of screening tests for breast and colorectal cancer.

A postsurgical circulating tumor DNA analysis after surgery and adjuvant chemotherapy may identify patients with stage III colorectal cancer at high risk of recurrence.

A compound called MRTX849 is showing signs of being the first effective inhibitor of the KRAS G12C-mutant subtype of non-small cell lung and colorectal cancers.

Immune checkpoint inhibitors have demonstrated impressive activity in patients with CRC and other solid tumors that are dMMR. Researchers explore the data. 

The worldwide incidence, and death toll, of colorectal and pancreatic cancers have sharply increased since 1990, according to the results of a new study.

The VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.

Extensive lymph node dissection with complete mesocolic excision resulted in significantly improved recurrence and survival outcomes in colon cancer.

A new combination may offer better survival for patients with BRAFV600E-mutated metastatic colorectal cancer.

A new combination may be key to improving tumor response rates and overall survival in colorectal cancer.

As more younger adults are diagnosed with colorectal cancer, the FDA approved Cologuard, a stool-based, at-home colorectal cancer screening, for adults aged 45 to 49 years.

The ACHIEVE study is one of six that are part of a global collaborative effort to evaluate the noninferiority of 3-month vs 6-month oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer.

A new study looked at the physical activity among patients with metastatic colorectal cancer to see if it affected disease progression and overall survival.

The phase II study compared single-agent anti-EGFR panitumumab to panitumumab combined with fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer.

A new study examined survival rates in patients with resected stage III colon cancer based on microsatellite instability and mismatch repair status.

In this article, we review the characteristics of the BRAF mutation and the evolving strategies for managing BRAF-mutant metastatic colorectal cancer.

This slideshow reviews the latest guidelines and updates on colorectal cancer screening.

Cancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.

Data from the randomized OSLO-COMET trial were presented at ASCO 2019, revealing the survival of laparoscopic vs open surgery for liver metastases in colorectal cancer.

A longer progression-free survival with FOLFOXIRI plus bevacizumab was noted in patients with metastatic colorectal cancer with poor prognosis.

Dr. Sinicrope reviews the phase III ATOMIC trial, which is testing standard chemotherapy alone or in combination with the anti–PD-L1 antibody atezolizumab as adjuvant therapy in a subset of colon cancer patients.